The 11 most recent market catalysts affecting $KYMR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152
Stifel analyst Alex Thompson has maintained a 'Buy' rating for Kymera Therapeutics (KYMR) and raised the price target from $132 to $152. This action signals increased analyst confi…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 65
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144
B of A Securities analyst Tazeen Ahmad has maintained a 'Buy' rating on Kymera Therapeutics (KYMR) and raised the price target from $123 to $144. This action signals increased anal…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Kymera Therapeutics Says Enrollment Completed In Phase 2b BROADEN2 Trial Of KT-621 In Atopic Dermatitis, With Topline Data Expected By Year-End 2026; Phase 3 Trials Planned To Initiate By Mid-2027
The completion of enrollment in a Phase 2b trial is a crucial de-risking event for Kymera Therapeutics (KYMR). The market will now keenly await the topline data by year-end 2026, w…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170
Guggenheim analyst Brad Canino has maintained a 'Buy' rating on Kymera Therapeutics (KYMR) and significantly raised the price target from $135 to $170. This action signals a strong…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on Kymera Therapeutics and significantly raised the price target from $116 to $151. This analyst action signals …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle has maintained an 'Overweight' rating on Kymera Therapeutics and raised the price target from $133 to $139. This action signals continued bullish sent…
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 65
Deutsche Bank Initiates Coverage On Kymera Therapeutics with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang has initiated coverage on Kymera Therapeutics (KYMR) with a 'Hold' rating and a price target of $120. This event is significant for KYMR as it mar…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Kymera Therapeutics (KYMR) and raised the price target from $125 to $135. This action signals continued confidence in th…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 65
Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140
Mizuho analyst Joseph Catanzaro maintained an 'Outperform' rating on Kymera Therapeutics and raised the price target from $120 to $140. This upward revision in the price target sig…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 75
Kymera Therapeutics shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform.
This downgrade by RBC Capital is a significant event for Kymera Therapeutics as it directly impacts investor sentiment and institutional buying interest. While not a 'sell' rating,…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.